Tuning of release kinetics in hydrogels

Patent metadata

Field	Value
Publication number	US-11559489-B2
Application number	US-201916541715-A
Country	US
Kind code	B2
Filing date	Aug 15, 2019
Priority date	Jul 9, 2018
Publication date	Jan 24, 2023
Grant date	Jan 24, 2023

Abstract

The present disclosure is directed to methods for tuning the release profile of a biologic disposed in a hydrogel. Parameters that can be used for the tuning include a molar ratio of a nucleophilic group to an electrophilic group, the number of the nucleophilic groups in the first precursor, the number of the electrophilic groups in the second precursor, the molecular weight of the first precursor, the molecular weight of the second precursor, a weight ratio of the biologic and excipient to the hydrogel, a weight percentage of the biologic in a solid state formulation, and a ratio of surface area to volume of the hydrogel. The methods described herein allow the formation of hydrogel with different release profiles suitable for different therapeutic applications.

First claim

The invention claimed is:

1. A method of producing a hydrogel having a biologic and excipient disposed therein with a desired release profile for the biologic, wherein the biologic and excipient is in a solid state formulation prior to being disposed in the hydrogel, wherein the hydrogel is characterized by a desired release period of about one week to about six months for at least 90% biologic release, the method comprising:
predetermining a weight ratio of the biologic and excipient to the hydrogel in the range of 60% to 90%,
predetermining at least one of the following parameters:
(a) the number of nucleophilic groups in a first precursor;
(b) the number of electrophilic groups in a second precursor;
(c) the molecular weight of the first precursor;
(d) the molecular weight of the second precursor;
(e) a weight percentage of the biologic in the solid state formulation; and
(f) a ratio of surface area to volume of the hydrogel;

determining a molar ratio of the total number of moles of the nucleophilic group to the total number of moles of the electrophilic group alone, or in combination with any one or more of the above parameters that is not predetermined, until the desired release profile is achieved, wherein the molar ratio of the nucleophilic group to the electrophilic group is in the range of 1.1 to 2; and
crosslinking the first precursor and the second precursor at the determined molar ratio around the solid state formulation under anhydrous conditions.

2. The method of claim 1 , wherein the molar ratio of the total number of moles of the nucleophilic group to the total number of moles of the electrophilic group is in the range of 1.5 to 2.0.

3. The method of claim 1 , wherein the molar ratio of the total number of moles of the nucleophilic group to the total number of moles of the electrophilic group is in the range of 1.3 to 1.8.

4. The method of claim 1 , wherein the biologic is a recombinant protein.

5. The method of claim 4 , wherein the recombinant protein is an antibody or a Trap protein (a fusion protein with decoy receptor domains).

6. The method of claim 1 , wherein the nucleophilic group comprises a primary amine or a primary thiol.

7. The method of claim 1 , wherein the electrophilic group comprises succinimide, succinimide ester, n-hydroxysuccinimide, maleimide, succinate, nitrophenyl carbonate, aldehyde, vinylsulfone, azide, hydrazide, isocyanate, diisocyanate, tosyl, tresyl, or carbonyldiimidazole.

8. The method of claim 1 , wherein the number of the nucleophilic groups in the first precursor is in the range of about 2 to about 10.

9. The method of claim 1 , wherein the number of the electrophilic groups in the second precursor is in the range of about 2 to about 10.

10. The method of claim 1 , wherein the weight percentage of the biologic in the solid state formulation is between about 30% to about 95%.

11. The method of claim 1 , wherein the desired release profile comprises:
(a) a release period of about two months to six months for at least 90% biologic release;
(b) a release period of about one week to two months for at least 90% biologic release;
(c) near-linear release of the biologic over at least one week;
(d) a delayed-release portion;
(e) a sigmoidal shape;
(f) a linear portion;
(g) a near-linear portion;
(h) a logarithmic portion;
(i) an exponential portion;
or a combination thereof.

12. The method of claim 1 , wherein the crosslinking occurs in the presence of an organic solvent that is anhydrous and hydrophobic.

13. The method of claim 12 , wherein the organic solvent is methylene chloride, ethyl acetate, dimethyl carbonate, chloroform, or a combination thereof.

14. The method of claim 1 , wherein the determining step is performed with a predictive model.

15. The method of claim 14 , wherein the molar ratio has a continuous effect on release profile in the predictive model.

16. The method of claim 14 , wherein the molecular weights of the first and second precursors have a non-continuous effect on release profile in the predictive model.

17. A method of producing a hydrogel having a biologic and excipient disposed therein, wherein the biologic and excipient is in a solid state formulation prior to being disposed in the hydrogel, and wherein the hydrogel is characterized by a desired release period of about one week to about six months for at least 90% biologic release, the method comprising:
selecting a first precursor that comprises two or more nucleophilic groups, wherein the first precursor has a molecular weight in the range of about 1 kDa to about 100 kDa;
selecting a second precursor that comprises two or more electrophilic groups, wherein the second precursor has a molecular weight in the range of about 1 kDa to about 100 kDa;
selecting a weight ratio of the biological and excipient to the hydrogel in the in the range of 60% to 90%;
determining at least one of the following parameters alone, or in combination, until the desired release period is achieved:
(a) a molar ratio of the total number of moles of the nucleophilic group to the total number of moles of the electrophilic group;
(b) a weight percentage of the biologic in the solid state formulation; and
(c) a ratio of surface area to volume of the hydrogel; and
crosslinking the first precursor and the second precursor at the determined molar ratio around the solid state formulation under anhydrous conditions, wherein the molar ratio of the total number of moles of the nucleophilic group to the total number of moles of the electrophilic group is in the range of 1.1 to 2.

18. The method of claim 17 , wherein the molar ratio of the total number of moles of the nucleophilic group to the total number of moles of the electrophilic group is in the range of 1.5 to 2.0.

19. The method of claim 17 , wherein the molar ratio of the total number of moles of the nucleophilic group to the total number of moles of the electrophilic group is in the range of 1.3 to 1.8.

20. The method of claim 17 , wherein the biologic is a recombinant protein.

21. The method of claim 20 , wherein the recombinant protein is an antibody or a Trap protein (a fusion protein with decoy receptor domains).

22. The method of claim 17 , wherein the nucleophilic group comprises a primary amine or a primary thiol.

23. The method of claim 17 , wherein the electrophilic group comprises succinimide, succinimide ester, n-hydroxysuccinimide, maleimide, succinate, nitrophenyl carbonate, aldehyde, vinylsulfone, azide, hydrazide, isocyanate, diisocyanate, tosyl, tresyl, or carbonyldiimidazole.

24. The method of claim 17 , wherein the first precursor comprises about 2 to about 10 nucleophilic groups.

25. The method of claim 17 , wherein the second precursor comprises about 2 to about 10 electrophilic groups.

26. The method of claim 17 , wherein the weight percentage of the biologic in the solid state formulation is between about 30% to about 95%.

27. The method of claim 17 , wherein the desired release period comprises:
(a) a release period of about two months to six months for at least 90% biologic release;
(b) a release period of about one week to two months for at least 90% biologic release;
(c) near-linear release of the biologic;
(d) a delayed-release portion;
(e) a sigmoidal shape;
(f) a linear portion;
(g) a near-linear portion;
(h) a logarithmic portion;
(i) an exponential

Assignees

• Regeneron Pharma

Inventors

• Chen Hunter
• Schlesinger Erica
• Feindt James

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61K9/1682 Primary

  Processes · CPC title

• A61K9/1617

  Organic compounds, e.g. phospholipids, fats · CPC title

• C07K14/47

  from mammals · CPC title

• C07K2319/32

  fusions with soluble part of a cell surface receptor, "decoy receptors" · CPC title